ClinicalTrials.gg
CompletedNCT01323621Updated Feb 15, 2018Results posted

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg and Fluticasone Propionate 250mcg / salmeterol 50mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 51 sites in 6 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-02-15.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.

Enrollment
10th of 25
512 · median 229
Started
2011
with 3 others
Phase 3
7 of 25
none open now
Registered
2nd of 25
by date
Lead sponsor
21 of 25
GlaxoSmithKline

Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one is the 10th largest by enrollment, is one of 4 that started in 2011, is one of 7 in phase 3, and was the 2nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with COPD.

Read the detailed description

This is a randomized, double-blind, double-dummy, multi-centre parallel group study. Subjects who meet the eligibility criteria at Screening and meet the randomization criteria at the end of a 2-week Run-In period will enter a 12-week treatment period. There will be a 7-day Follow-up period after the treatment period.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written
  • Male or females ≥ 40 years of age
  • Established clinical history of by ATS/ERS definition
  • Females are eligible to enter and participate if of non-, or if of child bearing potential, has a negative serum pregnancy test at screening, and agrees to one of the acceptable methods listed in protocol, used consistently and correctly
  • Former or current smoker > 10 pack years
  • Post-albuterol spirometry criteria: /FVC ratio ≤ 0.70 and FEV1 ≤ 70% of predicted normal (NHANES III)

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of asthma
  • Subjects with other respiratory disorders including active tuberculosis, α1-antitrypsin deficiency, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
  • Lung volume reduction surgery within previous 12 months
  • abnormalities not due to by chest x-ray
  • Hospitalized for poorly controlled COPD within 12 weeks of Screening
  • Poorly controlled COPD 6 weeks prior to Screening, defined as acute worsening of COPD that is managed by the subject with or antibiotics or that requires treatment prescribed by a physician
  • Lower respiratory infection requiring antibiotics 6 weeks prior to Screening
  • Uncontrolled or clinically significant (in opinion of PI) cardiovascular, hypertension, neurological, psychiatric, renal, hepatic, immunological, endocrine, peptic ulcer disease, or hematological abnormalities
  • Carcinoma not in complete remission for at least 5 years
  • Subjects with history of to study medications (e.g., beta-agonists, corticosteroid) or components of inhalation powder (e.g., lactose, magnesium stearate)
  • Subjects with history of severe milk protein allergy that, in opinion of study physician, contraindicates subject's participation
  • Known/suspected history of alcohol or drug abuse in the last 2 years
  • Women who are pregnant or lactating or plan to become pregnant
  • Subjects medically unable to withhold albuterol and/or ipratropium 4 hours prior to spirometry testing at each study visit
  • Use of certain medications such as bronchodilators and corticosteroids for the protocol-specific times prior to Visit 1 (the Investigator will discuss the specific medications)
  • Long Term Oxygen Therapy (LTOT) or nocturnal oxygen therapy >12 hours a day
  • Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening or during the study
  • Non-compliance or inability to comply with study procedures or scheduled visits
  • Affiliation with investigator site
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
512 participants (actual)

Study arms

  • Experimental
    Fluticasone Furoate / GW642444 (vilanterol)

    Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)

    Drug: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg · Drug: Double-dummy placebo · Drug: Salbutamol as needed

  • Active comparator
    Fluticasone Propionate / salmeterol

    Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)

    Drug: Fluticasone Propionate 250mcg / salmeterol 50mcg · Drug: Double-dummy placebo · Drug: Salbutamol as needed

Interventions

  • DrugFluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg

    Drug page: Fluticasone furoate

    inhalation powder

  • DrugFluticasone Propionate 250mcg / salmeterol 50mcg

    Drug page: Fluticasone

    inhalation powder

  • DrugDouble-dummy placebo

    inhalation powder

  • DrugSalbutamol as needed

    inhalation powder

06

What researchers measure

Primary outcomes

  1. Change From Baseline Trough in 24-Hour Weighted Mean FEV1 on Treatment Day 84

    Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean was calculated from the pre-dose FEV1 and the post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 4, 6, 8, 12, 13, 14, 16, 20, and 24 hours post-dose on Treatment Day 84. Baseline trough FEV1 was calculated as the mean of the two assessments made 30 and 5 minutes pre-dose on Treatment Day 1. Change from Baseline was calculated as the average of the Day 84 values minus the Baseline value. Analysis of covariance (ANCOVA) was conducted with covariates for country, smoking status, reversibility, and Baseline FEV1.

    Time frame: Baseline (Day 1) and Day 84

Secondary outcomes

  1. Time to Onset on Treatment Day 1

    Time to onset on Treatment Day 1 is defined as the time to an increase of 100 milliliters (mL) from Baseline in FEV1. Time to onset was calculated over 0 to 4 hours (5 min, 15 min, 30 min, 60 min, 120 min, and 240 min) post-dose.

    Time frame: Baseline and Day 1

07

Results

Posted Feb 6, 2014

Participant flow

2-week, Single-blind Run In Period
Participant flow — 2-week, Single-blind Run In Period
MilestonePlacebo + SalbutamolFSC 250/50 µg BIDFF/VI 100/25 µg QD
Started73900
Completed51100
Not completed22800
Withdrew: Not met inclusion/exclusion criteria12100
Withdrew: Physician decision700
Withdrew: Withdrawal by subject1200
Withdrew: Protocol violation100
Withdrew: Lost to follow-up100
Withdrew: Did not meet continuation criteria8600
12-week, Double-blind Treatment Period
Participant flow — 12-week, Double-blind Treatment Period
MilestonePlacebo + SalbutamolFSC 250/50 µg BIDFF/VI 100/25 µg QD
Started0252259
Completed0237239
Not completed01520
Withdrew: Adverse event015
Withdrew: Lack of efficacy026
Withdrew: Protocol violation044
Withdrew: Lost to follow-up010
Withdrew: Physician decision021
Withdrew: Withdrawal by subject054

Outcome measures

PrimaryChange From Baseline Trough in 24-Hour Weighted Mean FEV1 on Treatment Day 84

Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean was calculated from the pre-dose FEV1 and the post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 4, 6, 8, 12, 13, 14, 16, 20, and 24 hours post-dose on Treatment Day 84. Baseline trough FEV1 was calculated as the mean of the two assessments made 30 and 5 minutes pre-dose on Treatment Day 1. Change from Baseline was calculated as the average of the Day 84 values minus the Baseline value. Analysis of covariance (ANCOVA) was conducted with covariates for country, smoking status, reversibility, and Baseline FEV1.

Time frame:
Baseline (Day 1) and Day 84
Reported as:
Least squares mean · Liters
Change From Baseline Trough in 24-Hour Weighted Mean FEV1 on Treatment Day 84
LitersFSC 250/50 µg BIDFF/VI 100/25 µg QD
Change From Baseline Trough in 24-Hour Weighted Mean FEV1 on Treatment Day 840.114 ± 0.01830.142 ± 0.0182
Statistical analysis
  • FSC 250/50 µg BID vs FF/VI 100/25 µg QD · ANCOVA · p = 0.267 · Least squares mean difference: 0.029 · 95% CI -0.022 to 0.080ANCOVA analysis was conducted with covariates for country, smoking status, reversibility, and Baseline FEV1.
SecondaryTime to Onset on Treatment Day 1

Time to onset on Treatment Day 1 is defined as the time to an increase of 100 milliliters (mL) from Baseline in FEV1. Time to onset was calculated over 0 to 4 hours (5 min, 15 min, 30 min, 60 min, 120 min, and 240 min) post-dose.

Time frame:
Baseline and Day 1
Reported as:
Median · Minutes
Time to Onset on Treatment Day 1
MinutesFSC 250/50 µg BIDFF/VI 100/25 µg QD
Time to Onset on Treatment Day 130 (5 to 240)16 (5 to 240)

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FSC 250/50 µg BID—3/252 (1.2%)10/252 (4%)
FF/VI 100/25 µg QD—5/259 (1.9%)12/259 (4.6%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventFSC 250/50 µg BIDFF/VI 100/25 µg QD
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/2520/259
Comminuted fractureInjury, poisoning and procedural complications1/2520/259
Wrist fractureInjury, poisoning and procedural complications1/2520/259
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/2521/259
Bronchitis chronicRespiratory, thoracic and mediastinal disorders0/2521/259
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2521/259
Respiratory failureRespiratory, thoracic and mediastinal disorders0/2521/259
Cardiac failureCardiac disorders0/2521/259
Myocardial infarctionCardiac disorders0/2521/259
Infective tenosynovitisInfections and infestations0/2521/259
Most frequent other events
Most frequent other events
EventFSC 250/50 µg BIDFF/VI 100/25 µg QD
HeadacheNervous system disorders10/25212/259

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FSC 250/50 µg BIDFF/VI 100/25 µg QDTotal
Mean61.7 ± 9.0561.6 ± 9.5961.6 ± 9.32
Sex: Female, Male
Sex: Female, Male(Participants)FSC 250/50 µg BIDFF/VI 100/25 µg QDTotal
Female8578163
Male167181348
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)FSC 250/50 µg BIDFF/VI 100/25 µg QDTotal
White - White/Caucasian/European Heritage238241479
African American/African Heritage141731
White - Arabic/North African Heritage011
08

Study locations

51 sites
  • GSK Investigational Site
    Jasper, Alabama 35501, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Coeur d'Alene, Idaho 83814, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55402, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Gaffney, South Carolina 29340, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Seneca, South Carolina 29678, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Boerne, Texas 78006, United States
  • GSK Investigational Site
    Luebeck, Schleswig-Holstein 23552, Germany
  • GSK Investigational Site
    Napoli, Campania 80131, Italy
  • GSK Investigational Site
    San Felice A Cancello Caserta, Campania 81027, Italy
  • GSK Investigational Site
    Telese Terme (BN), Campania 82037, Italy
  • GSK Investigational Site
    Parma, Emilia-Romagna 43100, Italy
  • GSK Investigational Site
    Roma, Lazio 00185, Italy
  • GSK Investigational Site
    Rozzano (MI), Lombardia 20089, Italy
  • GSK Investigational Site
    Torrette (AN), Marche 60126, Italy
  • GSK Investigational Site
    Cagliari, Sardegna 09126, Italy
  • GSK Investigational Site
    Palermo, Sicilia 90146, Italy
  • GSK Investigational Site
    Firenze, Toscana 50134, Italy
  • GSK Investigational Site
    Padova, Veneto 35128, Italy
  • GSK Investigational Site
    Benoni, Gauteng 1501, South Africa
  • GSK Investigational Site
    Bellville, 7531, South Africa
  • GSK Investigational Site
    Bloemfontein, 9301, South Africa
  • GSK Investigational Site
    Cape Town, 7572, South Africa
  • GSK Investigational Site
    George, 6529, South Africa
  • GSK Investigational Site
    Port Elizabeth, 6045, South Africa
  • GSK Investigational Site
    Reiger Park, 1459, South Africa
  • GSK Investigational Site
    Somerset West, 7130, South Africa
  • GSK Investigational Site
    Thabazimbi, 0380, South Africa
  • GSK Investigational Site
    Witbank, 1034, South Africa
  • GSK Investigational Site
    Alicante, 03114, Spain
  • GSK Investigational Site
    Córdoba, 14004, Spain
  • GSK Investigational Site
    Lugo, 27003, Spain
  • GSK Investigational Site
    Mérida (Badajoz), 06800, Spain
  • GSK Investigational Site
    Ponferrada (León), 24411, Spain
  • GSK Investigational Site
    Valladolid, 47005, Spain
  • GSK Investigational Site
    Cherkassy, 18009, Ukraine
  • GSK Investigational Site
    Donetsk, 83099, Ukraine
  • GSK Investigational Site
    Kharkiv, 61002, Ukraine
  • GSK Investigational Site
    Kharkiv, 61035, Ukraine
  • GSK Investigational Site
    Kiev, 03680, Ukraine
  • GSK Investigational Site
    Kyiv, 03038, Ukraine
  • GSK Investigational Site
    Kyiv, 03049, Ukraine
  • GSK Investigational Site
    Kyiv, 04107, Ukraine
  • GSK Investigational Site
    Mykolayiv, 54003, Ukraine
  • GSK Investigational Site
    Vinnytsia, 21018, Ukraine
09

References and documents

Publications

  • Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. Respir Med. 2014 Aug;108(8):1171-9. doi: 10.1016/j.rmed.2014.05.008. Epub 2014 Jun 19. PubMed 24998880 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 2 years 1 month after primary completion. A results delay was requested in Dec 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2011
First posted
Mar 25, 2011
Start
Mar 18, 2011
Primary completionActual
Jan 1, 2012
CompletionActual
Jan 24, 2012
Results delay requested
Dec 13, 2012
Results first posted
Feb 6, 2014
Last update
Feb 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01323621
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 25, 2011
Start date
Mar 18, 2011
Primary completion
Jan 1, 2012
Completion
Jan 24, 2012
Results posted
Feb 6, 2014
Last update
Feb 15, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion